Hong Kai du, MD
Interventional Pain Medicine · Belleville, ILNPI 1396846598
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,975 of the $4,555 with a category attached, or 65.3%. 12 manufacturers reported payments, led by Boston Scientific at 36.2% of the total. Reporting peaked in 2019 at $3,840 and has fallen 95.4% since, to $176 in 2025.
Across 58 payments — averaging $78.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Si-bone, Inc.$1K
- Vertos Medical, Inc.$908
- Stryker$463
- Biotronik NRO, Inc.$176
- Nevro Corp.$174
- plus $156 from 6 others
What the payments were for
- Travel & lodging$2,97565%
- Food & beverage$1,58135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $1,649 |
| Si-bone, Inc. | 5 | $1,029 |
| Vertos Medical, Inc. | 12 | $908 |
| Stryker | 7 | $463 |
| Biotronik NRO, Inc. | 1 | $176 |
| Nevro Corp. | 10 | $174 |
| Abbott | 3 | $64 |
| Johnson & Johnson | 2 | $28 |
| Foundation Fusion Solutions, LLC | 1 | $22 |
| Pfizer | 1 | $18 |
| Medtronic | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,555 in reported general payments places this provider in the 60th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 447 | $6,322 |
| Tizanidine Hcl | 168 | $1,698 |
| Pregabalin | 28 | $679 |
| Meloxicam | 152 | $467 |
| Cyclobenzaprine Hcl | 22 | $242 |
| Cephalexin | 35 | $205 |
| Celecoxib | 26 | $155 |
| Levofloxacin | 39 | $119 |
| Famotidine | 18 | $53 |
| Prednisone | 17 | $40 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Belleville
- Alexander FeoktistovNorthfield$922K
- Timothy LubenowChicago$556K
- Sandeep AminChicago$430K
- Matthew JaycoxChicago$123K
- Hong VoChicago$91K
- Asokumar BuvanendranChicago$52K
- Ramsin BenyaminBloomington$32K
- Adam YoungChicago$29K
- Salman SagarwalaChicago$26K
- Jay JoshiDeer Park$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.